159 related articles for article (PubMed ID: 32100182)
1. FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease.
King-Kallimanis BL; Wroblewski T; Kwitkowski V; De Claro RA; Gwise T; Bhatnagar V; Farrell AT; Kluetz PG
Qual Life Res; 2020 Jul; 29(7):1903-1911. PubMed ID: 32100182
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
Rahmat LT; Logan AC
Drugs Today (Barc); 2018 May; 54(5):305-313. PubMed ID: 29911695
[TBL] [Abstract][Full Text] [Related]
4. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
Jaglowski SM; Blazar BR
Blood Adv; 2018 Aug; 2(15):2012-2019. PubMed ID: 30108109
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
Miklos D; Cutler CS; Arora M; Waller EK; Jagasia M; Pusic I; Flowers ME; Logan AC; Nakamura R; Blazar BR; Li Y; Chang S; Lal I; Dubovsky J; James DF; Styles L; Jaglowski S
Blood; 2017 Nov; 130(21):2243-2250. PubMed ID: 28924018
[TBL] [Abstract][Full Text] [Related]
6. Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.
Merkel EC; Mitchell SA; Lee SJ
Biol Blood Marrow Transplant; 2016 Apr; 22(4):752-758. PubMed ID: 26751003
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
Waller EK; Miklos D; Cutler C; Arora M; Jagasia MH; Pusic I; Flowers MED; Logan AC; Nakamura R; Chang S; Clow F; Lal ID; Styles L; Jaglowski S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2002-2007. PubMed ID: 31260802
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.
Le RQ; Wang X; Zhang H; Li H; Przepiorka D; Vallejo J; Leong R; Ma L; Goldberg KB; Pazdur R; Theoret MR; De Claro A
Oncologist; 2022 Jun; 27(6):493-500. PubMed ID: 35363318
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE Study.
Carpenter PA; Kang HJ; Yoo KH; Zecca M; Cho B; Lucchini G; Nemecek ER; Schultz KR; Stepensky P; Chaudhury S; Oshrine B; Khaw SL; Harris AC; Verna M; Zubarovskaya L; Lee Y; Wahlstrom J; Styles L; Shaw PJ; Dalle JH
Transplant Cell Ther; 2022 Nov; 28(11):771.e1-771.e10. PubMed ID: 36044977
[TBL] [Abstract][Full Text] [Related]
10. Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.
Vasconcellos de Souza C; Vigorito AC; Miranda ECM; Garcia C; Rensi Colturato VA; Mauad MA; Rodrigues Moreira MC; da Silva Bouzas LF; Lermontov S; Hamerschlak N; Rodrigues M; Carlos de Almeida Barros J; Chiattone R; Lee SJ; Flowers MED
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1313-1318. PubMed ID: 27058616
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Dubovsky JA; Flynn R; Du J; Harrington BK; Zhong Y; Kaffenberger B; Yang C; Towns WH; Lehman A; Johnson AJ; Muthusamy N; Devine SM; Jaglowski S; Serody JS; Murphy WJ; Munn DH; Luznik L; Hill GR; Wong HK; MacDonald KK; Maillard I; Koreth J; Elias L; Cutler C; Soiffer RJ; Antin JH; Ritz J; Panoskaltsis-Mortari A; Byrd JC; Blazar BR
J Clin Invest; 2014 Nov; 124(11):4867-76. PubMed ID: 25271622
[TBL] [Abstract][Full Text] [Related]
13. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
Martini DJ; Chen YB; DeFilipp Z
Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
[TBL] [Abstract][Full Text] [Related]
14. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice.
Schutt SD; Fu J; Nguyen H; Bastian D; Heinrichs J; Wu Y; Liu C; McDonald DG; Pidala J; Yu XZ
PLoS One; 2015; 10(9):e0137641. PubMed ID: 26348529
[TBL] [Abstract][Full Text] [Related]
17. Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.
Rosenthal EA; Ho PS; Joe GO; Mitchell SA; Booher S; Pavletic SZ; Baird K; Cowen EW; Comis LE
Support Care Cancer; 2020 Aug; 28(8):3679-3689. PubMed ID: 31811481
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease.
Treister N; Li S; Kim H; Lerman M; Sultan A; Alyea EP; Armand P; Cutler C; Ho V; Koreth J; Antin JH; Soiffer R
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2084-2091. PubMed ID: 27590106
[TBL] [Abstract][Full Text] [Related]
19. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
20. Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease.
Ali F; Ilyas A
Curr Res Transl Med; 2022 Jul; 70(3):103343. PubMed ID: 35339032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
